News

Physician-researchers at Cedars-Sinai Medical Center, in California, are developing brain and eye imaging techniques to improve the diagnosis and management of multiple sclerosis (MS). MS is characterized by the progressive loss of myelin, the fatty protective sheath around nerve fibers, in the brain and spinal cord due to abnormal…

Treatment with Gilenya (fingolimod) for up to four years was found safe and lowered relapse rates among people with multiple sclerosis (MS) in the Czech Republic, according to a real-world study called GOLEMS. Older age, lower disability level, and fewer relapses prior to the treatment’s start were all…

Atara Biotherapeutics plans to launch two Phase 3 clinical trials of its investigational immunotherapy ATA188 in people with non-active, progressive forms of multiple sclerosis (MS). Whether efforts for these trials will go forward, however, depends on positive results from an interim analysis of the Phase 2 portion of the…

Greater engagement in social activities and positive social support were associated with better physical and psychological health among people with multiple sclerosis (MS) in a recent study. These data “suggest that social integration and social support should be a crucial part of MS management,” the researchers wrote, adding that…

Repeat harvesting of bone marrow cells and infusing them back into the bloodstream is safe and feasible in people with active progressive multiple sclerosis (MS), according to data from a small, proof-of-concept clinical trial. Results were detailed in the study, “Repeat infusion of autologous bone marrow…

People newly diagnosed with multiple sclerosis (MS) in Norway have in recent years received disease-modifying therapies (DMTs) independent of their socioeconomic status, according to a new analysis. These findings do not support previous reports indicating that fewer DMTs are prescribed for the most socially deprived MS patients, the…

A Phase 1/2 clinical trial evaluating Imcyse’s experimental therapy IMCY-0141 in people with relapsing-remitting multiple sclerosis (RRMS) has dosed its first patient. The trial, called IMCY-MS-001, is expected to enroll nearly 150 adults with RRMS; sites were not disclosed in a release by the Belgium-based company. Interim results may be available…

The National Institute for Health and Care Excellence (NICE) has added oral Vumerity (diroximel fumarate), approved to treat relapsing-remitting multiple sclerosis (RRMS) in the U.K., to the list of medications available through the public health program for England. Because the therapy has been recommended through a fast track appraisal process, Vumerity…

An intervention that involves training to recognize facial expressions, and also mimicking these expressions, may help people with multiple sclerosis (MS) who have trouble recognizing facial affect, according to data from a small clinical trial. These findings were reported in the study “Emotional processing intervention (EMOPRINT):…

Electrically stimulating certain regions of the brain may help to ease tremors in people with multiple sclerosis (MS), but the specific brain regions needed for stimulation may be unique in MS compared to other tremor-causing diseases, a new study suggests. The study, “Connectomic analysis of unilateral dual-lead…

The Australian government has announced that a record AU$18 million (about $13.5 million) from the Medical Research Future Fund will be used to support research into multiple sclerosis (MS) as part of its 2022–23 budget. Grant opportunities will focus on increasing access to clinical trials and speeding the development of effective…

Based on findings from the first two secondary progressive multiple sclerosis (SPMS) patients given foralumab nasal spray, an experimental therapy, the U.S. Food and Drug Administration (FDA) has approved starting treatment in up to eight other patients under a special access program. Those enrolled in this intermediate-size expanded access…

Simoa, a technology that detects relevant molecules in samples with up to 1,000 times greater sensitivity than conventional methods, has helped to advance research into a blood biomarker expected to predict future disease activity in multiple sclerosis (MS) patients. Specifically, Quanterix‘s ultra-sensitive technology allowed an international team…

About CA$1.35 million ($1.07 million) has been invested in a project that seeks to understand the effects of multiple sclerosis (MS) on a group of people with pediatric-onset disease as they move into adulthood. The three-year investment was from Biogen Canada and Roche Canada — each providing about…

Many people with multiple sclerosis (MS) report new bouts of depression and anxiety as a result of the COVID-19 pandemic, but factors that often influence such mental health concerns were not associated with anxiety or depression in the patient group  surveyed for a recent U.S. study. “We found that…

Symptoms of Sjögren’s syndrome, including dry eyes and mouth, were observed among 16 people with multiple sclerosis (MS), three of whom met the diagnostic criteria for Sjögren’s in a recent study. Given this low number, however, it’s unclear if there is a true association between the two diseases,…

NVG-291, an experimental therapy designed to promote nervous system repair, has so far been well tolerated in an ongoing Phase 1 study with healthy volunteers. “The Phase 1 study is progressing very well, and we are encouraged by the data we are seeing so far,” Daniel Mikol, MD, PhD, chief…

While sexual problems are relatively common in women with multiple sclerosis (MS), it can still be difficult to openly discuss their experiences with their doctor. A questionnaire especially tailored for women with MS called the Sexual Dysfunction Management and Expectations Assessment in Multiple sclerosis – Female (SEA-MS-F) may…

Nearly three of every four participants in the CONSONANCE clinical trial, which is evaluating Ocrevus (ocrelizumab) in people with primary or secondary progressive multiple sclerosis (MS), showed no evidence of disease progression after a year of treatment. That’s according to new data presented at the American Academy of…

This year’s Scientific Breakthrough Award, funded by the American Brain Foundation, has been awarded to Stephen Hauser, MD, for helping to understand the genetic basis, immune processes, and treatment of multiple sclerosis (MS). The award recognizes the work of an individual or a team whose research has contributed…

Treatment with Kesimpta (ofatumumab) for more than three years revealed no new or unexpected safety findings, and continued to slow disability progression and prevent the development of new brain lesions in people with relapsing multiple sclerosis (MS), according to new clinical trial data. Information from another trial also…

Long-term treatment with evobrutinib safely and effectively reduces the rate of relapses in adults with relapsing forms of multiple sclerosis (MS), according to 2.5 years of data from a Phase 2 extension study. These findings — supporting evobrutinib’s therapeutic potential in relapsing MS — were shared in an…

Ublituximab, an experimental therapy for relapsing multiple sclerosis (MS) patients, outperformed Aubagio on a number of disability-related outcomes in the ULTIMATE clinical trials, new data show. The findings were presented in a series of posters at the 2022 American Academy of Neurology (AAN) Annual Meeting, being held in…

Six weeks of aerobic exercise led to benefits in cognition, fatigue, and depression among people with relapsing-remitting multiple sclerosis (RRMS), which may be due to increases in blood levels of a hormone called irisin, according to data from a randomized, controlled trial. “Considering the high prevalence of neuropsychiatric symptoms…

COVID-19 does not seem to be linked to increased disability worsening or more relapses in the long term for people with relapsing-remitting multiple sclerosis (RRMS), an Iranian study suggests. The study was relatively small, the researchers noted, indicating that more research is needed in the future to determine the…

Infection with the herpes simplex virus does not increase the risk of multiple sclerosis (MS), according to a new analysis based on genetic data. The study, “Mendelian Randomization Analysis Suggests No Associations of Herpes Simplex Virus Infections With Multiple Sclerosis,” was published in Frontiers in…

Mapi Pharma announced that it has been granted a U.S. patent covering the use of GA Depot, a potential long-acting formulation of glatiramer acetate, in people with progressive forms of multiple sclerosis (MS). The U.S. Patent and Trademark Office patent, No. 11,167,003, is titled, “…

Multiple sclerosis (MS) patients treated with Betaseron (interferon beta-1b) had over 90% treatment compliance — the percentage of doses administered — over one year, according to a study of data collected by the BETACONNECT autoinjector and the myBETAapp. After one year, the number of patients still using Betaseron…

Rexall Care Network, a nonprofit organization that is part of the Rexall Pharmacy Group, has launched a campaign to bolster the MS Society of Canada‘s initiatives to support caregivers of people living with multiple sclerosis (MS). The Bubble Campaign, which began March 27 and runs through April 30,…

The National Multiple Sclerosis Society (NMSS) has detailed its Pathways to Cures Roadmap and potential ways of addressing gaps and advancing each of the pathways, with a final goal of finding a cure for multiple sclerosis (MS) in all its forms. Details were in the report, “…